VolitionRx Completes $7 Million Registered Direct Offering

Represented VolitionRx, a company which, through its subsidiaries, is developing and commercializing simple, easy-to-use, cost-effective blood tests to diagnose and monitor a range of diseases, including some cancers, diseases associated with NETosis and sepsis, in raising approximately $7 Million through the sale of Common Stock and Pre-Funded Warrants, plus up to an additional $14.5 million upon the future exercise of milestone-linked warrants.